A recent clinical study conducted in the United States has shown that the intensive addition of a cholesterol-lowering drug to standard treatment can significantly reduce the risk of the first heart attack or stroke in high-risk diabetes patients.
Researchers at Brigham and Women's Hospital in the U.S. explained that the results demonstrate the benefits of early cholesterol reduction in protecting diabetes patients from heart attacks. The findings were published in the journal JAMA last Saturday.
Event Details
Diabetes is considered a major risk factor for heart disease and heart attacks, as prolonged high blood sugar levels can damage blood vessels and the heart, contributing to the accumulation of fats and cholesterol within the arteries. Diabetes patients often suffer from high blood pressure or dyslipidemia, which increases the likelihood of arterial blockages and heart crises. Key steps to mitigate these risks include controlling blood sugar levels, following a healthy diet, and engaging in regular physical activity.
The clinical trial included 3,655 patients with high-risk diabetes, such as those who have had diabetes for over 10 years, require daily insulin, or have microvascular diseases. Participants received either evolocumab injections every two weeks or a placebo, while all participants continued standard cholesterol treatment, including statins and ezetimibe.
After 48 weeks, it was found that evolocumab reduced harmful cholesterol levels by nearly 60%, contributing to a 31% reduction in the risk of experiencing the first heart attack, stroke, or death due to heart disease compared to standard treatment alone.
Background & Context
Over a follow-up period of nearly five years, the evolocumab group recorded a first major cardiovascular event rate of 5% compared to 7.1% in the placebo group. The study also showed that the rates of side effects were similar between the two groups, indicating that the treatment was well-tolerated among this patient population.
Researchers noted that for over a decade, the use of intensive cholesterol-lowering treatments had been limited to patients with known heart disease. They emphasized that these results demonstrate that early cholesterol reduction can prevent the first heart attack or stroke in high-risk diabetes patients, even before significant atherosclerosis develops.
Impact & Consequences
The use of evolocumab or similar intensive treatments may lead to changes in medical recommendations for the prevention of cardiovascular diseases in high-risk groups. The team indicated that the broader application of this treatment could reduce mortality rates and serious heart diseases among millions of diabetes patients worldwide.
These findings represent an important step toward improving healthcare for diabetes patients, as they could contribute to the development of new strategies for preventing heart attacks, reflecting the significance of scientific research in enhancing quality of life.
Regional Significance
Heart diseases are among the leading causes of death in Arab countries, with increasing rates of incidence among diabetes patients. Therefore, the results of this study may have positive implications for health policies in the region, reinforcing the importance of early prevention and treatment.
In conclusion, this study serves as evidence of the importance of ongoing research in the field of medicine and prevention, opening new horizons for improving the health of diabetes patients in the Arab world.